Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists

Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinica...

Full description

Bibliographic Details
Main Authors:	Mateusz Małkowski, Agnieszka Almgren-Rachtan, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek, Piotr Chłosta
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Pharmaceuticals
Subjects:	overactive bladder overactive bladder pharmacotherapy real-life data everyday clinical practice solifenacin storage symptoms
Online Access:	https://www.mdpi.com/1424-8247/17/1/116

Similar Items

Persistence and adherence of solifenacin treatment for Japanese women with overactive bladder
by: Minoru Kobayashi, et al.
Published: (2012-10-01)

Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms
by: Chen-Hsun Ho, et al.
Published: (2010-10-01)

Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis
by: Sergio Iannazzo, et al.
Published: (2008-03-01)

Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis
by: I Gede Yogi Prema Ananda, et al.
Published: (2025-01-01)

Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder
by: Yan Hu, et al.
Published: (2024-04-01)

Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol
by: Qian Wen, et al.
Published: (2020-07-01)

THE EFFICACY COMPARISON OF MIRABEGRON AS A MONOTHERAPY VERSUS ITS COMBINATION WITH SOLIFENACIN IN OVERACTIVE BLADDER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: Hasan Madani, et al.
Published: (2021-07-01)

Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01)

A rare case report of levofloxacin- and solifenacin-induced acute anaphylactic reaction in an elderly patient
by: Satish Eknath Bahekar, et al.
Published: (2019-01-01)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
by: Nastaran Majdinasab, et al.
Published: (2023-02-01)

Transcutaneous tibial neurostimulation and Solifenacin in urgent incontinence of postmenopausal women
by: Hojjat Radinmehr, et al.
Published: (2023-06-01)

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months
by: Carlo Vecchioli-Scaldazza, et al.

Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome
by: Megha O. Raj, et al.
Published: (2024-08-01)

Predictors of non-persistence in women with overactive bladder syndrome
by: Sheng-Mou Hsiao
Published: (2024-03-01)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
by: Seong Cheol Kim, et al.
Published: (2021-05-01)

Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo
by: Rachel A. High, et al.
Published: (2020-09-01)

Electroacupuncture to treat with Overactive Bladder in Postmenopausal Women: study protocol for a multicenter, randomized, controlled, parallel clinical trial
by: Eun-Young Nam, et al.
Published: (2018-09-01)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
by: Cheng-Ling Lee, et al.
Published: (2023-01-01)

Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial
by: M.A. Elbaset, et al.
Published: (2019-09-01)

Differences in bladder neck angles between female patients with overactive bladders and healthy peers
by: Mehmet Yoldas, et al.
Published: (2024-06-01)

Medical management of overactive bladder
by: Sarvpreet S Ubee, et al.
Published: (2010-01-01)

Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses
by: Martin C. Michel, et al.
Published: (2022-12-01)

Overactive Bladder Symptoms Negatively Affect Sleep Quality of Patients With Depression
by: Mikolaj Przydacz, et al.
Published: (2021-03-01)

Clinical Experience of the Use of Tolterodine in Patients with Overactive Bladder at Siriraj Hospital
by: Vitaya Titapant, et al.
Published: (2020-08-01)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
by: Hoon Choi, et al.
Published: (2018-03-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

The sensory system is a target for pharmaceutical therapy of overactive bladder
by: Christopher R. Chapple
Published: (2024-09-01)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
by: Mete Özkidik, et al.

Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)

Cerebellar Ataxia and Overactive Bladder after Encephalitis Affecting the Cerebellum
by: Megumi Sugiyama, et al.
Published: (2009-07-01)

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment
by: Aram Kim, et al.
Published: (2017-01-01)

ONABOTULINUM TOXIN-A FOR OVERACTIVE BLADDER
by: Mahmood Shakir Abdulkarim
Published: (2016-12-01)

The Urobiome and Its Role in Overactive Bladder
by: Sangrak Bae, et al.
Published: (2022-09-01)

Clustering of patients with overactive bladder syndrome
by: James Gross, et al.
Published: (2021-03-01)

Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder
by: Ana M. Fernández-Alonso, et al.
Published: (2025-12-01)

An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude
by: Mehmet Ali Sekeroglu, et al.
Published: (2016-05-01)

Overactive Bladder during Pregnancy: A Prospective Longitudinal Study
by: Hung-Ju Chen, et al.
Published: (2022-02-01)

Effect of caffeine on bladder function in patients with overactive bladder symptoms
by: Supatra Lohsiriwat, et al.
Published: (2011-01-01)

Evaluation of quality of life in women with overactive bladder (a survey)
by: F N Makhmejanova
Published: (2014-04-01)

MORPHOFUNCTIONAL FEATURES OF OVERACTIVE BLADDER IN THE SETTINGS OF RAPID BODY GROWTH
by: Mota O. M., et al.
Published: (2018-11-01)